A.J. Kazimi
Chairman & Chief Executive Officer
Gordon R. Bernard, M.D.
Director
Martin E. Cearnal
Director, Chief Commercial Officer and Senior, Vice President
Jonathan Griggs
Director
Joey Jacobs
Director
James Jones
Director
Thomas R. Lawrence
Director
A.J. Kazimi
Chief Executive Officer
Martin E. Cearnal
Senior Vice President, Chief Commercial Officer
Leo Pavliv, R.Ph
Senior Vice President, Operations & Chief Development Officer
Rick S. Greene
Chief Financial Officer & Vice President, Finance & Accounting
James L. Herman
Vice President, National Accounts & Corporate Compliance Officer
Amy Dix Rock, PH.D.
Senior Director, Regulatory & Scientific Affairs
Kelly A. Menzel
Director of Hospital Sales
Cindy Patton
Director, Sales and Marketing
Todd Anthony
Director, Sales Training
Barry Lee
Product Director
Tan Cheow Choon
Director, International Business
Michael Bonner
Director, Financial & Tax Reporting
John Lane
Director, Corporate Development & Treasurer

We are Leading the Way.

Leadership Team

A.J. Kazimi

Chairman & Chief Executive Officer

 

Mr. Kazimi has over twenty years’ experience in the international biopharmaceutical industry. He has served as Chief Executive Officer and Chairman of the Board of Directors of Cumberland Pharmaceuticals, a specialty pharmaceutical firm headquartered in Nashville since the Company’s inception in 1999. The Company was twice named to the Inc. 500 list of fastest growing private firms in the U.S. prior to its Initial Public Offering and listing on the NASDAQ stock exchange in 2009. More recently Cumberland was named one of the 40 fastest growing healthcare companies headquartered in the U.S. by Modern Healthcare Magazine in a listing that included hospital, physician, payers/insurers and supplier companies of all sizes.

Prior to forming Cumberland, Mr. Kazimi served as President and Chief Operating Officer of Therapeutic Antibodies Inc., an international biopharmaceutical company. During his eleven years with the company, he oversaw operations in three countries and played a key role in the company's product development programs and licensing agreements. During his tenure the company completed over $100 million in financings culminating in an IPO on the London stock exchange. Earlier in his career, he worked at Brown-Forman Corporation, a Fortune 500 company rising through a series of management positions.

Mr. Kazimi currently serves on the board of directors for the Nashville Health Care Council and Nashville Sports Council. He also serves as Chairman of CET a biomedical incubator and joint initiative among Cumberland, Vanderbilt University and the state of Tennessee’s Technology Development Corporation He has previously served on the boards of the Tennessee Biotechnology Association and Aegis Sciences Corporation, a federally certified forensic toxicology laboratory. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt Owen Graduate School of Management.


Member of the Compensation Committee;
Chair of the Nominating Committee 

Gordon R. Bernard, M.D.

Director

 

Dr. Bernard served as our Medical Director from 1999 until 2010 and currently serves as an advisor to the Company as Chair of our Medical Advisory Board. He has served on our Board of Directors since 2010. Dr. Bernard is the Associate Vice-Chancellor for Research at Vanderbilt University, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, first hand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs. The Board believes Dr. Bernard’s medical background is extremely valuable as the Company seeks to continue expanding its pipeline with promising products that offer advancement to patient care and are well-positioned competitively.

Martin E. Cearnal

Director, Chief Commercial Officer and Senior, Vice President

 

Mr. Cearnal has served as a member of our Board of Directors since 2004. In 2008, he joined our management team to head commercial development for Cumberland, currently serving as Senior Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000, and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has 44 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He serves the industry through several organizations, including the Coalition for Healthcare Communication and the National Task Force on CME Provider/Industry Collaboration. He has a B.S. degree from Southeast Missouri State University. The Board believes Mr. Cearnal brings significant marketing-related knowledge to the Company, which has and will help facilitate successful product launches and marketing plans, among other things.

Jonathan Griggs

Director

 

Mr. Griggs has served as a member of our Board of Directors since 2010. His career spans more than 40 years in the pharmaceutical and biotechnology industries and includes significant international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility, culminating with his position as Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the successful integration of three pharmaceutical businesses into what became Parke Davis, the largest consolidation in the industry at that time. From 1992 to present he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting start-up companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA (Antique Auto Club of America) Museum, a leading transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He has been an advisor to Cumberland Pharmaceuticals as a member of the Company’s Pharmaceutical Advisory Board since it began operations in 1999. The Board believes Mr. Griggs’ experience in strategic management and human resources consulting will be critical as the Company continues to build a strong, effective management team.

 


Member of the Compensation Committee;
Chair of the Nominating Committee 

Joey Jacobs

Director

 

Mr. Jacobs joined Cumberland’s Board of Directors in 2011 and is a member of the Nominating Committee. A healthcare veteran with more than 35 years of industry experience, Mr. Jacobs is currently the Chairman and Chief Executive Officer of Acadia Healthcare, a rapidly growing behavioral health company. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. (PSI), which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities, including President of HCA’s Tennessee Division. Mr. Jacobs’ background at HCA also includes serving as President of HCA’s Central Group, Vice President of the Western Group, Assistant Vice President of the Central Group and Assistant Vice President of the Salt Lake City Division. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also the past director of the Federation of American Hospitals and the National Association of Psychiatric Health Systems. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Mental Health Management. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University. The Board believes Mr. Jacobs’ extensive hospital industry experience as well as his prior experience as chairman and CEO of a publicly traded healthcare company will be critical as the Company continues to develop its hospital acute care product line and navigate the responsibilities associated with being a public company.

James Jones

Director

 

Mr. Jones has served as a member of our Board of Directors since 2010. Mr. Jones’ 35 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006, he has served as an advisor and provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committee of Argent Trust Company of Tennessee. Mr. Jones also serves as a member of our Audit Committee and is our Audit Committee financial expert. Mr. Jones holds a B.S. from Mississippi College and an M.B.A from Mississippi State University. The Board believes Mr. Jones’ significant accounting background will strengthen Cumberland’s existing financial capabilities and play a key role as the Company is subject to increasingly stringent accounting and auditing regulations as a public entity.

Thomas R. Lawrence

Director

 

Mr. Lawrence has served as a member of our Board of Directors since 1999. Since 2003 he has been Chairman of Aetos Technologies Inc., a corporation formed in 2003 by Auburn University to market technological breakthroughs by its faculty. Since 1998, Mr. Lawrence advises business clients on matters of marketing and corporate governance through his firm Capital Consultants. He previously served as Co-Founder and Managing Partner of Delta Capital Partners, or Delta, in Memphis from 1989 to 1998. The partnership made investments in ten early-stage companies which, by 1998, were valued at more than $30 million. Prior to the formation of Delta, Mr. Lawrence founded several companies in the areas of commercial leasing and venture capital financing. He also worked for most of the 1980s as an Institutional Sales Representative and Commercial Leasing Specialist with the Investment Banking Group of Union Planters Bank in Memphis, where he was responsible for the structure and sale of over $1 billion in securities. Mr. Lawrence serves as the Chairman of our Compensation Committee, as a member of our Audit Committee and our Nominating Committee and as a director for CET. He holds a B.A. from Mississippi State University. The Board believes Mr. Lawrence has played a significant role in guiding the Company’s strategy, and that he will continue to offer valuable services in directing Cumberland’s growth. He is currently a majority owner of the publishing company Front Porch Press, LLC.

A.J. Kazimi

Chief Executive Officer

 

Mr. Kazimi founded Cumberland Pharmaceuticals in 1999 and has served as Chief Executive Officer and Chairman of the Board of Directors since its inception. Prior to forming Cumberland, he served as President and Chief Operating Officer of Therapeutic Antibodies Inc., a biopharmaceutical company. During his 11 years with the company, Mr. Kazimi oversaw operations in three countries and played a key role in the company’s product development strategies, licensing and distribution agreements, and the raising of more than $100 million through equity and debt financings, as well as its initial public offering. Earlier in his career, he worked at Brown-Forman Corporation, rising through a series of management positions. Mr. Kazimi currently serves on the board of directors for the Nashville Health Care Council, an industry association representing the largest concentration of healthcare companies in the United States and has served on the board for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies, Inc. (CET). He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

Martin E. Cearnal

Senior Vice President, Chief Commercial Officer

 

Prior to joining Cumberland as Senior Vice President of Commercial Development in 2008, Mr. Cearnal served as President and Chief Executive Officer of Physicians World. During his 15-year tenure, the company became the largest provider of continuing medical education before its acquisition by Thomson Healthcare in 2000. He served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. During his more than 44 years in the healthcare industry, Mr. Cearnal has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox®, and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles, culminating in his position as Vice President, Marketing for International Operations. Mr. Cearnal has also served on Cumberland’s Board of Directors since 2004. He is a graduate of Southeast Missouri State University.

Leo Pavliv, R.Ph

Senior Vice President, Operations & Chief Development Officer

  As Senior Vice President of Operations, Mr. Pavliv is responsible for Cumberland’s overall drug development, including manufacturing and quality operations. Prior to joining Cumberland in 2003, he spent six years at Cato Research, a contract research organization where he served in a variety of positions, including Vice President of Pharmaceutical Development. Previously, he held scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis, Agouron Pharmaceuticals, ProCyte, and Interferon Sciences. He is a registered pharmacist (R.Ph.) and is regulatory affairs certified (RAC). Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.

Rick S. Greene

Chief Financial Officer & Vice President, Finance & Accounting

  Mr. Greene joined the Company in 2011 and is responsible for the Company’s accounting and finance activities. He has more than 20 years of experience in healthcare related financial management and reporting. Prior to joining Cumberland, Mr. Greene worked with Crowe Horwath’s Tennessee healthcare practice, whereas Market Leader he developed and led a financial advisory team serving private equity firms, technology, pharmaceutical and other healthcare companies. Additionally, Mr. Greene served as Chief Financial Officer for Surgical Alliance Corporation, a specialty hospital company, and spent 14 years in various roles at Ernst & Young. A Certified Public Accountant, Mr. Greene holds a Bachelor of Science in Accounting from Carson-Newman College.

James L. Herman

Vice President, National Accounts & Corporate Compliance Officer

  As Vice President of National Accounts, Mr. Herman handles all national sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He also oversees corporate compliance efforts. Previously, he was with Solvay Pharmaceuticals where he served as Director of Managed Care, as well as Director of Trade Affairs and Customer Service. Earlier in his career, Mr. Herman spent eight years with Schwarz Pharma, where he held national sales leadership positions. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.

Amy Dix Rock, PH.D.

Senior Director, Regulatory & Scientific Affairs

 

Dr. Rock joined Cumberland in 2001 and built its Regulatory Affairs Department and infrastructure. In addition to managing all interactions between the company and the FDA, Dr. Rock oversees the preparation of pre-approval and post-approval regulatory submissions. She is also involved in protocol development and clinical trials management, overseeing Cumberland’s medical call center and supporting corporate compliance initiatives. She holds a B.A. from Washington University, a Ph.D. in Immunology from the University of Kentucky, and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

Kelly A. Menzel

Director of Hospital Sales

  Ms. Menzel joined our company to launch Acetadote as a Regional Hospital Sales Representative in the Mid-Atlantic in 2004. In addition to launching Acetadote, she acted as the Field Based Trainer and was then promoted to the Eastern District Regional Manager position in 2006. Ms. Menzel was named as Director of Hospital Sales in 2009, at the launch of Caldolor. She is responsible for all sales activities associated with Acetadote and Caldolor for the hospital division, which is comprised of 62 sales representatives and 7 District Managers throughout the country. Prior to working for Cumberland, Ms. Menzel was a Hospital Sales Representative for Roche Laboratories, selling injectable antibiotics and other injectable products to the hospital market. Previous to her entry into pharmaceuticals, Ms. Menzel held various management positions in the sales, hospitality, and banking industries, spanning 15 years. She has a Bachelor of Science degree from Towson University in Towson, Maryland.

Cindy Patton

Director, Sales and Marketing

  Since her arrival at Cumberland in January 2009, Ms. Patton has been responsible for the Kristalose® marketing strategy and tactics, as well as providing sales direction to the Field Sales Force. Ms. Patton began her industry career as a Ciba Geigy sales representative in 1983. Relocating to the Ciba Geigy corporate office in 1991, she served in the Customer Marketing Group, becoming the Director of Institutional Marketing in 1995. Following the merger that created Novartis, she held positions which included Lotensin Product Director and Ciba Novartis Sales Director for the New York Region. She graduated magna cum laude from Lambuth College with a B.B.A.

Todd Anthony

Director, Sales Training

  Mr. Anthony joined our company in 2010 as Director, Sales Training & Development. He is responsible for all training activities related to product knowledge and selling skills for our Sales Organization. He began his pharmaceutical career with Berlex Laboratories Inc. in 1991 and spent 19 years at that company which is now Bayer HealthCare Pharmaceuticals following the 2006 acquisition of Schering AG. While there he held positions of increasing responsibility including roles in Sales, Sales Training, Sales Management and Corporate Management/Leadership development. He has a BSN degree from D’Youville College in Buffalo, NY.

Barry Lee

Product Director

  In his role as Product Director, Mr. Lee is responsible for all marketing activities associated with the commercialization of Caldolor®, the company’s intravenous formulation of ibuprofen. Prior to joining the company in 2008, he spent 24 years with Bayer Healthcare Pharmaceuticals, Inc. There he held a variety of pharmaceutical sales and marketing positions and, most notably, was responsible for the launch of Yasmin® in 2001—one of the most successful industry product launches at that time. He earned a B.S. degree from Texas A&M University.

Tan Cheow Choon

Director, International Business

 

As Director of International Business, Tan Cheow Choon joined our company in 2011. He is responsible for executing Cumberland’s initiative to expand markets for its products across Asia, including establishing, building and managing the Company’s presence there. Prior to joining the Company, Choon was in a variety of senior management roles at international pharmaceutical firms, most recently as Vice President of Southeast Asia for Hospira Inc. Choon joined Hospira pursuant to the company’s 2007 acquisition of Mayne Pharma SEA Pte Ltd. (formerly known as Faulding Pharmaceuticals, or “Faulding”), and was instrumental in the successful integration of the two pharmaceutical companies activities in their Asian markets. During his 13-year tenure with Faulding, also a global provider of injectable hospital products, Choon served in a variety of senior management, business development and marketing capacities, playing a key role in growing Faulding’s presence in Asia. He has a Bachelor of Accountancy from the National University of Singapore and a MBA from Monash University in Australia.

Michael Bonner

Director, Financial & Tax Reporting

 

Michael Bonner joined Cumberland Pharmaceuticals Inc. as Director, Financial and Tax Reporting during 2013 and directs the preparation and filing of all SEC communications along with the identification and research of technical accounting issues. He directs all Sarbanes-Oxley compliance activities including the primary interaction with internal and external auditors and directs all tax activities and tax services with external tax professionals.  He has 13 years of experience in financial management, accounting and reporting, primarily within the health care industry. Prior to joining Cumberland, Mr. Bonner worked for over six years with Advocat Inc., a NASDAQ listed skilled nursing services provider, as Vice President of Accounting and Financial Reporting.  Prior to that, Mr. Bonner served in a financial reporting role at LifePoint Hospitals Inc., a NASDAQ listed acute care hospital company, and spent close to five years in the assurance practice at Ernst & Young. A Certified Public Accountant, Mr. Bonner holds both a Bachelor of Science in Accounting and a Masters of Business Administration from Troy University.

John Lane

Director, Corporate Development & Treasurer

 

As Director, Corporate Development he is responsible for Cumberland’s business development, investor relations and strategic planning activities. As Treasurer he oversees the management of the Company’s cash reserves and financing activities. Prior to joining Cumberland in 2009, Mr. Lane spent 13 years in investment banking during which he advised public and private companies across a variety of transaction types and industry sectors, including public and private equity and debt financings, buy-side and sell-side mergers and acquisitions, restructurings, valuations, fairness opinions and strategic advisory assignments. He was a founding member of Morgan Joseph & Co. Inc., most recently as a Director responsible for their private placement practice. Prior to Morgan Joseph, he was an Associate in the mergers & acquisitions group at ING Barings LLC. Prior to ING Barings, he was a member of the investment banking group at SunTrust Equitable Securities Corporation. Mr. Lane holds a Bachelor of Science in Finance from Indiana University.